Novo GLP-1 pill OK’d in U.S. for heart disease risk (NVO:NYSE) Seeking Alpha FDA Approves Novo Nordisk’s Rybelsus Diabetes Pill to Reduce Heart Risk The Wall Street Journal First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved New Atlas FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at …
Read More »